The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma.

Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF. Blood. 2016 Apr 26. pii: blood-2016-03-705319. [Epub ahead of print] PMID: 27118453 [PubMed - as supplied by publisher] READ MORE

Posted: May 26, 2016

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

Levin N, Spencer A, Harrison SJ, Chauhan D, Burrows FJ, Anderson KC, Reich SD, Richardson PG, Trikha M. Br J Haematol. 2016 May 9. doi: 10.1111/bjh.14113. [Epub ahead of print] PMID: 27161872 [PubMed - as supplied by publisher] READ MORE

Posted: May 26, 2016

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DV. Biol Blood Marrow Transplant. 2016 May 7. pii: S1083-8791(16)00190-7. doi: 10.1016/j.bbmt.2016.03.021. [Epub ahead of print] READ MORE

Posted: May 26, 2016

Page 26 of 87« First...1020...2425262728...405060...Last »